gefitinib

Trials studying gefitinib

• phase2Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Canceractive not recruitingn=48
• phase3AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancercompletedn=674
• phase2Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Aloneactive not recruitingn=29
• phase3A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)active not recruitingn=545
• phase1Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCactive not recruitingn=105
• phase1An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancercompletedn=8
• phase2Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)active not recruitingn=156
• phase3First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastasescompletedn=492